Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Tarsus Pharmaceuticals, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21
   10-Q10-Q10-Q10-Q10-Q10-K10-Q10-Q
Revenues:          
Total revenues          
Operating expenses:          
Cost of license fees and collaboration revenue     0.60.1 0.1 
Research and development    40.639.937.541.741.339.0
General and administrative    37.131.828.225.422.518.0
    Total operating expenses    63.557.537.0 16.9 
    Loss from operations before other income (expense) and income taxes    -62.1-54.9-42.4-12.2-9.2-3.6
   
Other income (expense):          
Interest income    1.40.3  0.00.0
Interest expense    -1.5-0.9-0.3   
Other (expense) income, net    0.10.10.0-0.1-0.1-0.1
    Total other income (expense), net    -1.2-1.9-2.3-1.6-1.3-1.0
Provision for income taxes    0.1 0.40.10.0-0.3
    Net (loss) income    -63.3-56.5-44.4-13.8-10.4-4.9
   
Other comprehensive loss:          
    Comprehensive loss    -63.4-56.5-44.4-13.8-10.4-4.9
   
Earnings Per Share [Abstract]          
Net loss per share, basic (usd per share)    ($2.78)($2.70)($2.15)($1.68)$0.45($2.50)
Net loss per share, diluted (usd per share)    ($2.78)($2.70)($2.17)($0.72)$1.41($1.54)
   
Weighted Average Number of Shares Outstanding, Diluted [Abstract]          
Weighted-average shares outstanding, basic (shares)    23.121.620.620.516.912.5
Weighted-average shares outstanding, diluted (shares)    23.121.621.021.217.713.2

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy